EP2437603A4 - Verfahren zur behandlung von hepatischer enzephalopathie - Google Patents

Verfahren zur behandlung von hepatischer enzephalopathie

Info

Publication number
EP2437603A4
EP2437603A4 EP10797501A EP10797501A EP2437603A4 EP 2437603 A4 EP2437603 A4 EP 2437603A4 EP 10797501 A EP10797501 A EP 10797501A EP 10797501 A EP10797501 A EP 10797501A EP 2437603 A4 EP2437603 A4 EP 2437603A4
Authority
EP
European Patent Office
Prior art keywords
methods
hepatic encephalopathy
treating hepatic
treating
encephalopathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP10797501A
Other languages
English (en)
French (fr)
Other versions
EP2437603A1 (de
Inventor
William Forbes
Enoch Bortey
Kunal Merchant
Audrey Shaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salix Pharmaceuticals Ltd
Original Assignee
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/572,344 external-priority patent/US20100204173A1/en
Application filed by Salix Pharmaceuticals Ltd filed Critical Salix Pharmaceuticals Ltd
Priority to EP21202634.8A priority Critical patent/EP3964066A1/de
Publication of EP2437603A1 publication Critical patent/EP2437603A1/de
Publication of EP2437603A4 publication Critical patent/EP2437603A4/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP10797501A 2009-06-02 2010-06-02 Verfahren zur behandlung von hepatischer enzephalopathie Ceased EP2437603A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP21202634.8A EP3964066A1 (de) 2009-06-02 2010-06-02 Verfahren zur behandlung von hepatischer enzephalopathie

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US18351309P 2009-06-02 2009-06-02
US12/572,344 US20100204173A1 (en) 2008-10-02 2009-10-02 Methods of treating hepatic encephalopathy
US26252509P 2009-11-18 2009-11-18
US30585410P 2010-02-18 2010-02-18
US30693510P 2010-02-22 2010-02-22
US30741710P 2010-02-23 2010-02-23
US31679610P 2010-03-23 2010-03-23
PCT/US2010/037131 WO2011005388A1 (en) 2009-06-02 2010-06-02 Methods of treating hepatic encephalopathy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP21202634.8A Division EP3964066A1 (de) 2009-06-02 2010-06-02 Verfahren zur behandlung von hepatischer enzephalopathie

Publications (2)

Publication Number Publication Date
EP2437603A1 EP2437603A1 (de) 2012-04-11
EP2437603A4 true EP2437603A4 (de) 2012-12-12

Family

ID=43429472

Family Applications (2)

Application Number Title Priority Date Filing Date
EP21202634.8A Pending EP3964066A1 (de) 2009-06-02 2010-06-02 Verfahren zur behandlung von hepatischer enzephalopathie
EP10797501A Ceased EP2437603A4 (de) 2009-06-02 2010-06-02 Verfahren zur behandlung von hepatischer enzephalopathie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP21202634.8A Pending EP3964066A1 (de) 2009-06-02 2010-06-02 Verfahren zur behandlung von hepatischer enzephalopathie

Country Status (9)

Country Link
EP (2) EP3964066A1 (de)
KR (3) KR20190099100A (de)
CN (1) CN102548408A (de)
AU (1) AU2010271070A1 (de)
BR (1) BRPI1010028A2 (de)
MX (1) MX2011012829A (de)
NZ (1) NZ596851A (de)
RU (1) RU2540513C2 (de)
WO (1) WO2011005388A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010040020A1 (en) * 2008-10-02 2010-04-08 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
MX2011013427A (es) * 2009-06-15 2012-04-20 Salix Pharmaceuticals Ltd Modulacion de exposicion sistemica a rifaximina.
CA2854380A1 (en) 2011-11-02 2013-05-10 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (ibs) and infections
MX2016016458A (es) * 2014-06-30 2017-07-13 Salix Pharmaceuticals Inc Métodos para repetir tratamiento de síndrome del intestino irritable (ibs).
JP2019501182A (ja) * 2016-01-08 2019-01-17 コロナリーコンセプツ エルエルシー 肝性脳症の処置のための治療剤の食品ベースの送達
RU2618394C1 (ru) * 2016-02-24 2017-05-03 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт психического здоровья" Средство для защиты биомолекул плазмы крови от воздействия этанола
GB2607265A (en) * 2021-03-31 2022-12-07 The Flame Lily Holdings Ltd Outputting a notification

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010040020A1 (en) * 2008-10-02 2010-04-08 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
US20020028764A1 (en) * 2000-09-04 2002-03-07 Aarhus Amt. Treatment of acute and chronic liver disease
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
US20040229948A1 (en) * 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010040020A1 (en) * 2008-10-02 2010-04-08 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BASS N ET AL: "93 RIFAXIMIN IS EFFECTIVE IN MAINTAINING REMISSION IN HEPATIC ENCEPHALOPATHY: RESULTS OF A LARGE, RANDOMIZED, PLACEBO-CONTROLLED TRIAL", JOURNAL OF HEPATOLOGY, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, vol. 50, 1 April 2009 (2009-04-01), pages S39, XP026495706, ISSN: 0168-8278, [retrieved on 20090401], DOI: 10.1016/S0168-8278(09)60095-7 *
JIANG Z D ET AL: "Rifaximin: In vitro and in vivo antibacterial activity - A review", CHEMOTHERAPY, vol. 51, 2005, pages 67 - 72, ISSN: 0009-3157 *
SALIX PHARMACEUTICALS ET AL: "Xifaxan Prescribing Information", 1 March 2008 (2008-03-01), pages 1 - 2, XP008139843, Retrieved from the Internet <URL:http://www.salix.com/assets/pdf/prescribe_into/xifaxanpi.pdf> *
See also references of WO2011005388A1 *
ZULLO ANGELO ET AL: "Rifaximin therapy and hepatic encephalopathy: Pros and cons.", WORLD JOURNAL OF GASTROINTESTINAL PHARMACOLOGY AND THERAPEUTICS 6 AUG 2012, vol. 3, no. 4, 6 August 2012 (2012-08-06), pages 62 - 67, ISSN: 2150-5349 *

Also Published As

Publication number Publication date
CN102548408A (zh) 2012-07-04
MX2011012829A (es) 2012-02-28
WO2011005388A1 (en) 2011-01-13
AU2010271070A1 (en) 2012-01-12
EP2437603A1 (de) 2012-04-11
KR20120025578A (ko) 2012-03-15
NZ596851A (en) 2013-10-25
RU2540513C2 (ru) 2015-02-10
EP3964066A1 (de) 2022-03-09
KR20190099100A (ko) 2019-08-23
KR20170036116A (ko) 2017-03-31
BRPI1010028A2 (pt) 2019-02-12
RU2011154138A (ru) 2013-07-20

Similar Documents

Publication Publication Date Title
IL212055A0 (en) Methods of treating hepatic encephalopathy
HK1255283A1 (zh) 用於治療流感的化合物和方法
HK1217763A1 (zh) 用於治療疾病的方法
ZA201203289B (en) Use of bethanechol for treatment of zerostomia
GB2473099B (en) Inspection of holes
EP2252318A4 (de) Verfahren zur behandlung von entzündungen
EP2437603A4 (de) Verfahren zur behandlung von hepatischer enzephalopathie
IL208354A0 (en) Methods of treatment
PL2502173T3 (pl) Projektowanie cząsteczek
GB0919097D0 (en) Treatment of hard surfaces
GB0915515D0 (en) Treatment of vasculoproliferative conditions
EP2461806A4 (de) Kleine antiangiogenese-moleküle und verwendungsverfahren dafür
EP2480579A4 (de) Verfahren zur behandlung von entzündungen
IL206491A0 (en) Treatment of produce
EP2408950A4 (de) Elektro-rückgewinnung von metallen
EP2501803A4 (de) Verfahren zur pluripotenzintensivierung
GB0907249D0 (en) New process and new compounds
EP2440238A4 (de) Behandlungsverfahren
IL216629A0 (en) Methods of treating inflammation
GB0904073D0 (en) Treatment of influenza
GB0915895D0 (en) Method of cleansing
GB0904164D0 (en) Method of treatment
GB0909807D0 (en) Method of treatment
GB0921823D0 (en) Method of treatment
PL386302A1 (pl) Nowa pochodna izotiazolopirydyny

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20111222

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME RS

A4 Supplementary search report drawn up and despatched

Effective date: 20121114

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/00 20060101ALI20121108BHEP

Ipc: A01N 43/42 20060101AFI20121108BHEP

Ipc: A61K 31/437 20060101ALI20121108BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1168992

Country of ref document: HK

17Q First examination report despatched

Effective date: 20131111

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

APBK Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNE

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20211015

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230521